B. Atiya

Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study

A. Ogdie, B. Zhu, N. Princic, 2021, ACR open rheumatology.

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months

R. Burge, A. Blauvelt, B. Zhu, 2021, Dermatology and Therapy.

Comparison of Two-Year Treatment Adherence, Persistence, Discontinuation, Re-initiation, and Switching Between Psoriasis Patients Treated with Ixekizumab or Secukinumab in Real-World Settings.

R. Burge, A. Blauvelt, B. Zhu, 2021, Journal of the American Academy of Dermatology.

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months

R. Burge, A. Blauvelt, B. Zhu, 2022, PharmacoEconomics - Open.

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry

R. Burge, B. Lockshin, B. Zhu, 2022, Dermatology and Therapy.

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry

B. Strober, R. Burge, B. Lockshin, 2021, Dermatologic therapy.

26718 Comparison of long-term treatment patterns between ixekizumab and secukinumab users among biologic-experienced psoriasis patients

R. Burge, A. Blauvelt, B. Zhu, 2021 .